GlassScriptPhysician profile
Manouchka Mildor
NPI 1265211395
$5,366.29
in general payments reported to CMS, 2019-2025
43 companies · $3,992 in 2025
The $3,992 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $416 · 2024: $958 · 2025: $3,992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,139 · Education: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,138.61 |
| Education | $227.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $943.56 | 2024-2025 | Rybrevant, Carvykti, Darzalex |
| Novartis Pharmaceuticals Corporation | $715.46 | 2023-2025 | Kisqali, Piqray |
| Abbvie INC. | $323.83 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $322.14 | 2024-2025 | Fruzaqla, Vpriv, Ninlaro |
| Celgene Corporation | $250.91 | 2025 | Reblozyl |
| Glaxosmithkline, LLC. | $245.02 | 2025 | Zejula, Jemperli, Ojjaara |
| Incyte Corporation | $219.42 | 2025 | Jakafi, Monjuvi, Niktimvo |
| Astellas Pharma US INC | $207.82 | 2025 | Vyloy, Xtandi |
| Pfizer INC. | $188.59 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $150.69 | 2025 | Enhertu, Tagrisso |
| Genzyme Corporation | $146.95 | 2025 | |
| Geron Corporation | $140.56 | 2025 | Rytelo |
| Legend Biotech USA INC. | $114.43 | 2025 | Carvykti |
| Pharmacyclics LLC, An Abbvie Company | $109.14 | 2023 | Imbruvica, Epkinly |
| Sanofi US Services INC. | $103.88 | 2025 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manouchka Mildor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.